Bayer: FDA Approves Finerenone For New Indication

(RTTNews) - Bayer announced that the FDA has approved finerenone or Kerendia for the treatment of adult patients with heart failure and a left ventricular ejection fraction of =40%. Finerenone is now indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adult patients with heart failure with LVEF of =40%.

The company said the new indication approval follows the FDA's Priority Review designation and is based on positive results from the Phase III FINEARTS-HF study, which is part of the ongoing MOONRAKER program.

For More Such Health News, visit rttnews.com.